Teladoc has reduced 2022 guidance due to unfavorable market dynamics, which will limit near-term upside potential of the shares. Long-term fundamental growth story remains intact.
Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare compa...